WO2009060608A1 - Ｓｄｆ－１を含有してなる徐放性組成物 - Google Patents

Ｓｄｆ－１を含有してなる徐放性組成物 Download PDF

Info

Publication number
WO2009060608A1
WO2009060608A1 PCT/JP2008/003204 JP2008003204W WO2009060608A1 WO 2009060608 A1 WO2009060608 A1 WO 2009060608A1 JP 2008003204 W JP2008003204 W JP 2008003204W WO 2009060608 A1 WO2009060608 A1 WO 2009060608A1
Authority
WO
WIPO (PCT)
Prior art keywords
sdf
sustained release
composition
release composition
composition containing
Prior art date
Application number
PCT/JP2008/003204
Other languages
English (en)
French (fr)
Inventor
Yasuhiko Tabata
Original Assignee
Ono Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.
Priority to AT08847868T priority Critical patent/ATE543507T1/de
Priority to US12/741,694 priority patent/US8435953B2/en
Priority to EP08847868A priority patent/EP2218459B1/en
Priority to JP2009539954A priority patent/JP5248519B2/ja
Priority to ES08847868T priority patent/ES2378918T3/es
Publication of WO2009060608A1 publication Critical patent/WO2009060608A1/ja
Priority to US13/771,511 priority patent/US9107953B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

　本発明の課題は、ＳＤＦ－１含有徐放性組成物の提供にある。本発明は、（１）ＳＤＦ－１と、（２）カルボキシル基および／またはスルホ基を有する修飾ゼラチンからなるハイドロゲルとを含有してなる徐放性組成物を提供する。該組成物は、生体内にて血管前駆細胞の集積を促すケモカインであるＳＤＦ－１を持続的に放出することができるので、種々の剤形の医薬組成物として、例えば、虚血性疾患や骨疾患の治療および／または症状進展抑制剤として使用可能である。
PCT/JP2008/003204 2007-11-07 2008-11-06 Ｓｄｆ－１を含有してなる徐放性組成物 WO2009060608A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT08847868T ATE543507T1 (de) 2007-11-07 2008-11-06 Sdf-1 enthaltende zusammensetzung mit anhaltender freisetzung
US12/741,694 US8435953B2 (en) 2007-11-07 2008-11-06 Sustained release composition containing SDF-1
EP08847868A EP2218459B1 (en) 2007-11-07 2008-11-06 Sustained release composition containing sdf-1
JP2009539954A JP5248519B2 (ja) 2007-11-07 2008-11-06 Ｓｄｆ−１を含有してなる徐放性組成物
ES08847868T ES2378918T3 (es) 2007-11-07 2008-11-06 Composición de liberación sostenida que contiene SDF-1
US13/771,511 US9107953B2 (en) 2007-11-07 2013-02-20 Sustained release composition containing SDF-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-289598 2007-11-07
JP2007289598 2007-11-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/741,694 A-371-Of-International US8435953B2 (en) 2007-11-07 2008-11-06 Sustained release composition containing SDF-1
US13/771,511 Division US9107953B2 (en) 2007-11-07 2013-02-20 Sustained release composition containing SDF-1

Publications (1)

Publication Number Publication Date
WO2009060608A1 true WO2009060608A1 (ja) 2009-05-14

Family

ID=40625516

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/003204 WO2009060608A1 (ja) 2007-11-07 2008-11-06 Ｓｄｆ－１を含有してなる徐放性組成物

Country Status (6)

Country Link
US (2) US8435953B2 (ja)
EP (1) EP2218459B1 (ja)
JP (1) JP5248519B2 (ja)
AT (1) ATE543507T1 (ja)
ES (1) ES2378918T3 (ja)
WO (1) WO2009060608A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821027B2 (en) 2011-08-23 2017-11-21 Mochida Pharmaceutical Co., Ltd. Method for regenerating cartilage comprising applying a monovalent metal salt of alginic acid and SDF-1
JP2020512338A (ja) * 2017-03-30 2020-04-23 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 腎臓疾患の治療方法
CN113144283A (zh) * 2021-04-26 2021-07-23 广东海洋大学 一种促进创伤愈合的TSCP-GelMA水凝胶及其制备和应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
AU2012268078B2 (en) * 2011-06-07 2017-06-01 Mesoblast International Sarl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
BR112016008267A2 (pt) 2013-10-22 2017-10-03 Viromed Co Ltd Composição para prevenir ou tratar esclerose lateral amiotrófica usando duas ou mais isoformas de fator de crescimento de hepatócito
EP3139945A4 (en) * 2014-05-08 2017-11-29 Wake Forest University Health Sciences Methods of treating incontinence and other sphincter deficiency disorders
WO2016048105A1 (ko) * 2014-09-26 2016-03-31 주식회사 바이로메드 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물
CN113403244B (zh) 2014-12-23 2022-08-19 伊利亚制药公司 伤口愈合的方法
WO2019032930A1 (en) * 2017-08-11 2019-02-14 Wake Forest University Health Sciences USE OF CXCL12 FOR THERAPY AFTER SURGERY OF THE PROSTATE

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027630A1 (fr) 1993-05-31 1994-12-08 Kaken Pharmaceutical Co., Ltd. Preparation de gel a base de gelatine reticulee contenant un facteur de croissance de fibroblaste de base
WO2003007982A1 (fr) 2001-07-18 2003-01-30 Yasuhiko Tabata Preparations d'hydrogel hgf a liberation prolongee
WO2004030691A1 (ja) * 2002-10-04 2004-04-15 Medgel Corporation Ｎｋ４を含有する徐放性製剤
WO2005120549A2 (en) * 2004-06-07 2005-12-22 Conor Medsystems, Inc. Local delivery of growth factors for stem cell transplantation
WO2006030887A1 (ja) * 2004-09-17 2006-03-23 Cellgentech, Inc. 外用皮膚潰瘍治療剤
WO2007080898A1 (ja) * 2006-01-10 2007-07-19 Medgel Corporation 徐放性ハイドロゲル製剤
JP2007289598A (ja) 2006-04-24 2007-11-08 Sanada Seiko Kk 食器収納器具

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2566798B1 (fr) * 1984-06-27 1986-12-12 Centre Nat Rech Scient Membrane porteuse de la luciferase pour le dosage de l'atp et son procede de production
US6297337B1 (en) * 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
GB0201674D0 (en) * 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2006000020A1 (en) 2004-06-29 2006-01-05 European Nickel Plc Improved leaching of base metals
BRPI0611707A2 (pt) 2005-06-29 2012-04-24 Compumedics Ltd conjunto de sensor com ponte condutiva

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994027630A1 (fr) 1993-05-31 1994-12-08 Kaken Pharmaceutical Co., Ltd. Preparation de gel a base de gelatine reticulee contenant un facteur de croissance de fibroblaste de base
WO2003007982A1 (fr) 2001-07-18 2003-01-30 Yasuhiko Tabata Preparations d'hydrogel hgf a liberation prolongee
WO2004030691A1 (ja) * 2002-10-04 2004-04-15 Medgel Corporation Ｎｋ４を含有する徐放性製剤
WO2005120549A2 (en) * 2004-06-07 2005-12-22 Conor Medsystems, Inc. Local delivery of growth factors for stem cell transplantation
WO2006030887A1 (ja) * 2004-09-17 2006-03-23 Cellgentech, Inc. 外用皮膚潰瘍治療剤
WO2007080898A1 (ja) * 2006-01-10 2007-07-19 Medgel Corporation 徐放性ハイドロゲル製剤
JP2007289598A (ja) 2006-04-24 2007-11-08 Sanada Seiko Kk 食器収納器具

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIOMATERIALS, vol. 19, 1998, pages 1781 - 9
CIRCULATION, vol. 109, 2004, pages 2454 - 2461
KOHEI MIYAO: "Practical Drug Delivery Systems", MEDICINE AND DRUG JOURNAL, 1986
LANCET, vol. 362, 2003, pages 697 - 703
NATURE MEDICINE, vol. 10, no. 8, 2004, pages 858 - 864

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9821027B2 (en) 2011-08-23 2017-11-21 Mochida Pharmaceutical Co., Ltd. Method for regenerating cartilage comprising applying a monovalent metal salt of alginic acid and SDF-1
JP2020512338A (ja) * 2017-03-30 2020-04-23 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 腎臓疾患の治療方法
CN113144283A (zh) * 2021-04-26 2021-07-23 广东海洋大学 一种促进创伤愈合的TSCP-GelMA水凝胶及其制备和应用
CN113144283B (zh) * 2021-04-26 2022-06-28 广东海洋大学 一种促进创伤愈合的TSCP-GelMA水凝胶及其制备和应用

Also Published As

Publication number Publication date
JP5248519B2 (ja) 2013-07-31
EP2218459A4 (en) 2011-06-01
US8435953B2 (en) 2013-05-07
US20130243824A1 (en) 2013-09-19
US9107953B2 (en) 2015-08-18
ATE543507T1 (de) 2012-02-15
US20100267612A1 (en) 2010-10-21
ES2378918T3 (es) 2012-04-19
JPWO2009060608A1 (ja) 2011-03-17
EP2218459B1 (en) 2012-02-01
EP2218459A1 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
WO2009060608A1 (ja) Ｓｄｆ－１を含有してなる徐放性組成物
MX2008000099A (es) Composiciones farmaceuticas de liberacion modificada novedosas, y procedimiento de preparacion de dichas composiciones.
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
MY147641A (en) Fast release paracetamol tablets
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
WO2006039336A3 (en) Conveniently implantable sustained release drug compositions
BR0316310A (pt) Composições farmacêuticas tendo um veìculo modificado
WO2002007722A3 (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
EP3492069A3 (en) Pharmaceutical compositions
MX2009005148A (es) Aptamero contra midcina, y uso del mismo.
IL175220A (en) 3,5-substituted estrone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for inhibiting 17beta-hydroxysteroid dehydrogenase type i enzyme
HK1149717A1 (en) Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
IL196891A (en) Annals @@@ - Amino - @@@@@@@ - Tetrahydro - H9 - Carbazole - 9 - Yl) - Acetic Acid, Containing Pharmaceuticals
AR054238A1 (es) Composicion farmaceutica que contiene una biguanida y un derivado de tiazolidindiona
WO2007053578A3 (en) Multi-phasic nitric oxide and drug co-eluting stent coatings
NZ594311A (en) Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration
BG109430A (en) FLUKOONAZOLE CAPSULES WITH IMPROVED EXEMPTION
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
NZ591408A (en) Paracetamol and Calcium carbonate composition
WO2003016563A3 (fr) Cible moleculaire de la neurotoxicite
WO2006138571A3 (en) Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance
WO2008078109A3 (en) Medicament
HK1120417A1 (en) Stable nanoparticle formulations
EA200900531A1 (ru) Фармацевтические составы
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08847868

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009539954

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12741694

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008847868

Country of ref document: EP